7:14AM Harvard Biosci announces details of approved spin-off of Harvard Apparatus Regenerative Technology; co will distribute all of its shares of HART common stock on a pro rata basis to those stockholders that hold HBIO common stock at the close of business on Oct 21, 2013 (HBIO) 5.05 : The Board of Directors of Harvard Bioscience has approved the spin-off of its wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, or HART. To implement the spin-off distribution, Harvard Bioscience will distribute all of its shares of HART common stock on a pro rata basis to those stockholders that hold Harvard Bioscience common stock at the close of business on October 21, 2013, the Record Date for the distribution. Each such shareholder of Harvard Bioscience common stock will receive one share of HART common stock for every four shares of Harvard Bioscience common stock that such shareholder holds at the close of business on the Record Date. The distribution will be effective as of November 1, 2013. As a result of the spin-off, Harvard Bioscience will no longer own any shares of HART common stock and HART will be an independent public company. The dividend of HART common stock will be issued in book-entry form only, which means that no physical HART stock certificates will be issued
Recent HBIO News
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/27/2026 11:30:21 AM
- Sidoti Events, LLC's May Micro-Cap Virtual Conference • ACCESS Newswire • 05/20/2026 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 08:30:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:30:18 AM
- Harvard Bioscience Announces First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/12/2026 11:30:00 AM
- Harvard Bioscience to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET • GlobeNewswire Inc. • 04/28/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/21/2026 08:58:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:56:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 01:57:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 01:44:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 01:48:04 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 03/23/2026 12:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 06:13:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:31:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:56:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 11:30:12 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 12:20:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 11:30:29 AM
- Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results • GlobeNewswire Inc. • 03/12/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 11:30:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 09:01:29 PM
- Harvard Bioscience Announces Reverse Stock Split • GlobeNewswire Inc. • 03/06/2026 09:01:00 PM
- Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
